MMF Rewind | CTI's Next Chapter: A Conversation with Jon Koch and Brian Lawrence

<p>This week, we&#39;re revisiting a previous conversation with Jon Koch, CEO, and Brian Lawrence, CFO and President, as they share their perspective on what’s next for CTI as the organization enters a new phase of growth. They reflect on CTI’s legacy of partnership and execution while outlining how they plan to expand its impact across complex clinical trials.</p><p>From scaling capabilities and investing in talent to strengthening operational discipline and embracing data-driven decision-making, Jon and Brian offer an inside look at how leadership alignment is shaping strategy. They also explore the evolving demands of the clinical research industry, from the need for predictability and site support to the practical application of technology and AI.</p><p>At its core, this conversation is about balancing growth with purpose: delivering for sponsors, strengthening teams, and ultimately improving outcomes for patients.</p><p><strong>00:36</strong> CTI Rewind: Revisiting CTI&#39;s leadership transition and future vision<br><strong>00:58</strong> Expanding CTI&#39;s reach in complex and advanced therapy trials<br><strong>02:23</strong> Disciplined growth strategy and sustainable global expansion<br><strong>04:38</strong> CTI&#39;s legacy of care, credibility, and partnership<br><strong>06:14</strong> Driving performance through metrics and accountability<br><strong>09:03</strong> Leadership alignment and partnership in action<br><strong>12:13</strong> Talent development, infrastructure, and AI enablement<br><strong>14:14</strong> Positioning CTI for continued growth in complex trials<br><strong>17:12</strong> Key industry trends: predictability, sites, and technology<br><strong>20:40</strong> Sustaining culture and employee experience<br><strong>22:08</strong> Long-term vision: scale, impact, and global presence<br><strong>25:15</strong> Closing takeaways: quality, people, and execution</p>